Partnership aims to bring accessible sleep testing and diagnosis to all audiences, including patients with limited access to care
MADISON, WI – August 13, 2024 – Today, EnsoData, a pioneer in healthcare AI, and Nonin, a leader in pulse oximetry devices, announce a partnership to address the underserved and undiagnosed sleep apnea patient population with a collaborative Type IV testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an affordable solution to test for sleep apnea at home.
Obstructive sleep apnea (OSA) is an increasingly common condition. If left untreated, OSA exacerbates many other cardiac, respiratory, metabolic, neurodegenerative, and mental health problems. It affects almost 1 billion people globally. This includes 425 million who have moderate to severe OSA. Severe OSA is characterized by 30 or more apnea events per hour. This manifests in a cycle where patients stop breathing once every other minute. This partnership aims to address this patient population by delivering a collaborative solution to help improve overall population health metrics.
EnsoData and Nonin offer affordable, non-invasive at home sleep testing for patients at risk of sleep apnea
EnsoSleep PPG is interoperable with compatible FDA-cleared pulse oximetry devices, which now includes the Nonin WristOx2® Model 3150, allowing the AI to analyze collected data and provide sleep staging and event detection analysis to sleep labs and clinicians using Nonin devices.
“This partnership is an important step toward increasing patient access to quality sleep care,” said Justin Mortara, CEO of EnsoData. “As a trusted manufacturer of high-quality pulse oximetry solutions, Nonin’s devices provide more innovative hardware options for our customers to use in conjunction with EnsoSleep PPG. We are excited to launch this collaboration and continue to grow the EnsoData network of sleep medicine partnerships.”
Nonin’s WristOx2® Model 3150 devices deliver fast, accurate oxygen saturation and pulse rate readings in challenging conditions, including low perfusion, reduced motion, and across skin pigmentations, by using sensors that provide continuous SpO2 monitoring and data recording.
“Customers that choose Nonin, choose quality and affordability,” said John Hastings, CEO of Nonin Medical. “Our durable noninvasive monitoring products provide reliable measurement performance. Combining this with EnsoData’s AI will help democratize sleep apnea diagnostics by reducing the cost of a home sleep study significantly.”
About Nonin: Since 1986, Nonin Medical has developed reliable technologies and manufactured durable noninvasive patient monitoring devices for healthcare professionals and consumers. Nonin pulse oximeters, cerebral and tissue oximeters, sensors, and software deliver dependable performance day after day. To learn more, visit nonin.com.
About EnsoData: EnsoData is a U.S.-based healthcare technology company. Ensodata offers AI solutions that connect sleep disorder diagnosis to therapy, empowering clinicians to efficiently diagnose and treat health conditions. Cleared by the FDA in 2024, EnsoSleep PPG offers the ability to AI score data provided by FDA-cleared pulse oximeters. Learn more at ensodata.com.
